Cover Image
市場調查報告書

Avastin(大腸癌症):市場預測與分析

Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 321682
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
Avastin(大腸癌症):市場預測與分析 Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023
出版日期: 2014年11月28日 內容資訊: 英文 57 Pages
簡介

Avastin是以血管新生途徑為標的的新藥物級最初的作用劑。血管新生抑制劑是人單株抗體IgG1抗體的一種,藉由與血管內皮層細胞生長因子-A(VEGF-A)結合,來阻止配體和VEGF受體的結合。VEGF途徑的阻礙因子,可阻止腫瘤增殖所需的狹皮細胞增大及新血管的形成。這個藥劑在單體治療上並無效果,必須與化療方案併用。

本報告提供大腸癌症的治療藥之一──Avastin(Bevacizumab)的全球市場相關分析,提供大腸癌症概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Avastin的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關的報告
  • 預定出版的相關調查報告

第3章 疾病概要

  • 病因與病情生理
    • 病因
    • 病理生理學
  • 臨床階段
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 篩檢及診斷
    • 治療的指南及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 Avastin (Bevacizumab)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄
Product Code: GDHC469DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Avastin was the first agent of a new class of drugs that targeted the angiogenesis pathway. The anti-angiogenic agent is a humanized monoclonal IgG1 that binds to vascular endothelial growth factor-A (VEGF-A), preventing the ligand from binding to the VEGF receptor. Inhibition of the VEGF pathway prevents endothelial cells from proliferating and forming the new bloods vessels that are required for the tumor to grow. The drug delivered as a monotherapy is not curative, and must be co-administered with a chemotherapy regimen.

Scope

  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Avastin for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Avastin performance
  • Obtain sales forecast for Avastin from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Screening and Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Avastin (Bevacizumab)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Colorectal Cancer Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Average Body Weight and Surface Area Across the 8MM
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: TNM and Staging Classification System for CRC
  • Table 2: Symptoms of Colorectal Cancer
  • Table 3: Treatment Guidelines for CRC
  • Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
  • Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
  • Table 6: Leading Treatments for CRC, 2014
  • Table 7: Product Profile - Avastin
  • Table 8: Avastin SWOT Analysis, 2014
  • Table 9: Global Sales Forecast ($m) for Avastin, 2013-2023
  • Table 10: Average Body Weight and Surface Area Across the 8MM
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Back to Top